Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-19
2005-04-19
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S230800, C514S235500, C514S318000, C514S352000, C514S407000, C514S447000, C544S058700, C544S131000, C544S146000, C546S194000, C546S309000, C548S371700, C549S068000
Reexamination Certificate
active
06881735
ABSTRACT:
The present invention relates to compounds of the formula Iwherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
REFERENCES:
patent: 6150356 (2000-11-01), Lloyd et al.
patent: 6511977 (2003-01-01), Lloyd et al.
patent: 6548547 (2003-04-01), Schindler et al.
patent: 197 44 027 (1999-04-01), None
patent: 0 908 456 (1999-04-01), None
patent: 2201083 (1974-04-01), None
patent: 876526 (1961-09-01), None
patent: 9631492 (1996-10-01), None
Lloyd et al., Chemical Abstracts, vol. 132:207763, 2000.*
Ferlux-Chimie S.A., Chemical Abstracts, vol. 82:16861, 1975.*
Alexander Mülsch, et al., “Purification of Heme-Containing Soluble Guanylyl Cyclase,”Methods in Enzymology,vol. 195, pp. 377-383, 1991.
Hirano et al., “Silver Halide Photographic Material,”Chemical Abstracts,119:105757f:726, 1993.
Nagaoka et al., “Color Photographic Material With Good Sharpness and Low Minimum Density,”Chemical Abstracts,120:41858a:807, 1994.
Fukagawa et al., “Direct Positive Color Photographic Material For Color Image Formation and Color Proof,”Chemical Abstracts,123:70224h:1043, 1995.
Matsumoto et al., “Silver Halide Color Photographic Material With Excellent Color Reproduction, Sharpness and Storage Stability,”Chemical Abstracts,126:257007u:1075, 1997.
Vesely, D.L., “B complex vitamins activate rat guanylate cyclase and increase cyclic GMP levels,”European Journal of Clinical Investigation,1985, 15:258-262.
Vesely, D.L., “Phencyclidine Stimulates Guanylate Cyclase Activity,”Biochemical and Biophysical Research Communications,1979, 88:4:1244-1248.
Ignarro, L.J., “Regulation of Cytosolic Guanylyl Cylase by Porphyrins and Metalloporphyrins,”Advances in Pharmacology,1994, 26:35-65.
Pettibone, D.J., et al., “A Structurally Novel Stimulator of Guanylate Cyclase With Long-Lasting Hypotensive Activity In The Dog,”European Journal of Pharmacology,1985, 116:307-312.
Yu, S.M., et al., “Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta,”British Journal of Pharmacology,1995, 114:1587-1594.
Ko, F.N., et al., “YC-1, a Novel Activator of Platelet Guanylate Cyclase,”Blood,1994, 84:12:4226-4233.
Yu, S.M., et al., “Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells,”Biochem. J.,1995, 306:787-792.
Wu, C.C., et al., “YC-1 inhibited human platelet aggregation through No-independent activation of soluble guanylate cyclase,”British Journal of Pharmacology,1995, 116:1973-1978.
Konishiroku Photo Industry Co.,Chemical Abstracts,vol. 102, abstract 140722, 1985.
Ikegami,Chemical Abstracts,vol. 122, abstract 92744, 1995.
Schindler Ursula
Schönafinger Karl
Strobel Hartmut
Aventis Pharma Deutschland GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Raymond Richard L.
LandOfFree
Sulfur substituted sulfonylaminocarboxylic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfur substituted sulfonylaminocarboxylic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfur substituted sulfonylaminocarboxylic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401744